

GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2013

Particulars	Rs. In Lacs						
	Quarter Ended 31.12.2013 Unaudited	Quarter Ended 30.09.2013 Unaudited	Quarter Ended 30.06.2013 Unaudited	Quarter Ended 31.12.2012 Unaudited	For the Period Ended 31.12.2013 Unaudited	For the Period Ended 31.12.2012 Unaudited	For the Year Ended 31.03.2013 Audited
INCOME:							
Net Sales / Income from Operations (Net of Excise Duty)	3130.89	2901.44	2536.92	2461.77	8569.25	7546.09	9998.31
Other Operating Income	4.84	1.89	2.33	14.77	9.06	28.77	42.45
Total Income from Operations (Net)	3135.73	2903.33	2539.25	2476.54	8578.31	7574.86	10040.76
EXPENSES:							
Cost of Materials Consumed	1299.25	1401.62	951.59	965.71	3652.46	2846.53	3287.68
Purchase of Stock-in-Trade	433.18	176.04	294.46	355.15	903.68	1151.71	1921.99
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(325.58)	138.72	83.25	(57.38)	(103.61)	(200.85)	(107.75)
Employee Benefits Expenses	433.09	249.11	144.05	130.20	826.25	368.99	544.85
Depreciation and Amortisation Expenses	61.38	57.76	63.00	50.99	182.14	153.64	217.95
Other Expenses	986.40	648.32	779.37	810.25	2414.09	2621.58	3278.98
Total Expenses	2887.72	2671.57	2315.72	2254.92	7875.01	6941.59	9143.70
Profit from Operations before Other Income, finance costs and Exceptional Items	248.01	231.76	223.53	221.62	703.30	633.27	897.06
Other Income	7.72	6.10	1.12	3.13	14.94	3.76	12.25
Profit from ordinary activities before finance costs and exceptional items	255.73	237.86	224.65	224.75	718.24	637.03	909.31
Finance Costs	100.16	87.30	102.08	94.25	289.54	235.58	383.00
Profit from ordinary activities after finance costs but before exceptional items	155.58	150.57	122.57	130.49	428.71	401.44	526.31
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit from Ordinary Activities Before Tax	155.58	150.57	122.57	130.49	428.71	401.44	526.31
Current Tax	42.50	23.57	43.00	45.40	109.07	139.90	149.50
Deferred Tax	6.45	12.26	0.00	0.00	18.71	0.00	53.19
Short/(Excess) Tax Provisions of Earlier Years	0.00	0.00	0.00	0.00	0.00	0.00	(9.30)
Net Profit from Ordinary Activities After Tax	106.63	114.74	79.57	85.09	300.93	261.54	332.92
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit for the Period	106.63	114.74	79.57	85.09	300.93	261.54	332.92
Paid up Equity Share Capital (Face Value of Rs 1/- Each)	773.50	773.50	773.50	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	1766.82	1660.19	1545.46	1439.46	1766.82	1439.46	1465.89
E.P.S	0.14	0.15	0.10	0.11	0.39	0.34	0.43
Public Shareholding							
-- Number of Shares of Rs 1/- Each	23222355	23222355	23222355	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%	30.02%	30.02%	30.02%
Promoters and Promoter group Shareholding							
a) Pledged / Encumbered							
-- Number of Shares of Rs 1/- Each	0	0	0	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered							
-- Number of Shares of Rs 1/- Each	54127645	54127645	54127645	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%	69.98%	69.98%	69.98%

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 15th February, 2014 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

For GUFIC BIOSCIENCES LTD.


 Pranav J. Choksi
 Executive Director

 Place: Mumbai
 Date: 15.02.2014

GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER ENDED 31.12.2013

Rs in Lacs

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Quarter Ended	For the	For the	For the
	31.12.2013 Unaudited	30.09.2013 Unaudited	30.06.2013 Unaudited	31.12.2012 Unaudited	Period Ended 31.12.2013 Unaudited	Period Ended 31.12.2012 Unaudited	Year Ended 31.03.2013 Audited
SEGMENT REVENUE							
Sales & Service							
Pharma	2822.90	2551.98	2291.38	2239.04	7666.26	6803.26	9085.06
Consumer	307.99	349.46	245.54	222.73	902.99	742.83	913.25
Total	3130.89	2901.44	2536.92	2461.77	8569.25	7546.09	9998.31
Unallocabel Income	12.56	7.99	3.45	17.90	24.00	32.53	54.70
Total Segment Revenue	3143.45	2909.43	2540.37	2479.67	8593.25	7578.62	10053.01
SEGMENT RESULTS							
Pharma	545.15	493.88	445.20	434.13	1484.23	1319.09	1761.51
Consumer	60.59	67.25	47.85	43.08	175.69	143.69	176.66
TOTAL	605.74	561.13	493.05	477.21	1659.92	1462.78	1938.17
Less: Unallocated over heads	288.63	265.51	205.40	201.47	759.54	672.12	810.91
Finance Charges	100.16	87.30	102.08	94.25	289.54	235.58	383.00
Depreciation	61.38	57.76	63.00	50.99	182.14	153.64	217.95
Tax provision	48.95	35.83	43.00	45.40	127.78	139.90	193.39
Net Profit after Tax	106.63	114.74	79.57	85.09	300.93	261.54	332.92

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 15th February, 2014 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

Investors Complaints received and disposed off during the Quarter Ended 31st December, 2013.

	Nos
Complaints Pending at the Beginning of the quarter	Nil
Complaints received during the quarter	7
Disposal of Complaints	7
Complaints lying unresolved at the end of the quarter	Nil

Previous periods' figures have been regrouped, rearranged, reworked or reclassified wherever necessary to confirm to the current periods' classification

For GUFIC BIOSCIENCES LTD.


 Pranav J. Choksi
 Executive Director

Date: 15.02.2014

Place: Mumbai

Certificate No. SHR/577/GBSL/2013 - 2014

CERTIFICATE

The
Board of Directors
Gufic Biosciences Limited
Mumbai

1. We have reviewed the accompanying statement of unaudited financial results of **GUFIC BIOSCIENCES LIMITED** for the period ended **December 31, 2013** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Attention is invited to:
 - a. We have been appointed as a Statutory Auditors of the Company at the AGM held on September 26, 2013 for the FY 2013 - 2014, subsequent to the close of previous quarter ended June 30, 2013, the financial results of previous quarters or periods and previous year as reported by management have been relied upon. We have also relied upon the opening account balances for the quarter ended September 30, 2013 as given by the management.
 - b. The company has recently introduced ERP system in stages and only certain modules are operational, accuracy of which are yet to be tested. The unaudited financial amounts for quarter December 31, 2013 and for the nine months period ended December 31, 2013 has been compiled from various sources by the management, including introduced ERP Modules. We have relied on management representation that it has taken enough care and diligence to ensure that the presented data and accounts, so compiled, are true & correct.
 - c. We are unable to express our opinion on the recoverability of certain debts, aggregating to Rs. 241.35 lacs, which continue to be outstanding for more than one year and of certain loans and advances of Rs. 158.44 lacs which are outstanding for more than two year. However, in the opinion of the management, the same are good and recoverable and thus no provision is required in respect thereof.



- d. *Inventory as valued, verified and certified by the management has been incorporated in the accounts.*
- e. *We have relied upon the segment wise report prepared by the management based on the nature of product, risk and returns, organization structure and internal reporting during the quarter. Based on management perception and reporting criteria the figures have been regrouped and reclassified wherever necessary.*
4. Based on our review conducted as above and **subject to our comments in para 3 above**, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the Accounting Standards notified under the Companies Act, 1956 (which continue to be applicable in respect of Section 133 of the Companies Act, 2013 in terms of General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S H R & CO
Chartered Accountants
FRN: 120491W



Deep N Shroff
Partner

M. No: 122592
Mumbai dated February 15, 2014

SHR & CO.
CHARTERED ACCOUNTANTS
212A/203, Rewa Chambers,
Sir Vithaldas Thakersey Marg,
Mumbai - 400 020.
FRN : 120491W